Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 Life Science Investing
Cizzle Brands Corporation Launches SnakStars Sport Bites: A Nut-Free, High-Protein, High-Fibre Snack Designed for Active Kids Biotech Investing
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Life Science Investing
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results Life Science Investing
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform Life Science Investing
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference Life Science Investing
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results Life Science Investing
Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026 Life Science Investing
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 Life Science Investing
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 Life Science Investing
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants Life Science Investing
